The NASH ambitions of Cymabay Therapeutics (CBAY) hit a wall Tuesday with the negative outcome of a mid-stage clinical trial.
In the Phase 2 study, three oral doses of its lead drug, called seladelpar, all performed worse than a placebo, based on a non-invasive imaging test that measures decreases in liver fat. The study had enrolled 181 patients with moderate stage of NASH and treated them for 12 weeks.
About the Author Reprints
